Skip to content

Clinical Relevance of the Reverse Lipopolysaccharide Transport Pathway in Patients With Acute Peritonitis

Clinical Relevance of the Reverse Lipopolysaccharide Transport Pathway in Patients With Acute Peritonitis An Observational Prospective Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04126577
Acronym
LIPS
Enrollment
27
Registered
2019-10-15
Start date
2019-12-19
Completion date
2022-10-27
Last updated
2023-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritonitis

Brief summary

When there is infection in the intra-abdominal area, bacteria secrete toxins that are absorbed by the peritoneum. These toxins then bind to lipoproteins (which carry cholesterol in the blood) and are eliminated by the liver. Phospholipid transfer protein (PLTP) is a protein that facilitates the binding of bacterial toxins to lipoproteins and thus their elimination. The objective of this study is to study the relationship between PLTP and the elimination of bacterial toxins in humans. A better understanding of the elimination of these toxins will lead to a better understanding of the disease. The ultimate objective is to improve the management of intra-abdominal infections.

Interventions

BIOLOGICALblood samples

4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.

Sponsors

Centre Hospitalier Universitaire Dijon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* person who has given oral consent (patient or family member) * pre-operative SEPSIS criteria (qSOFA \>=2) or vasopressor or mechanical ventilation treatment * admitted to the operating room for suspected generalized secondary peritonitis

Exclusion criteria

* person not affiliated to national health insurance * person under legal protection (curatorship, guardianship) * person under court order * pregnant, parturient or breastfeeding woman * minor * immunosuppression (HIV infection, corticosteroid treatment \> 0.15 mg/kg/day prednisolone equivalent \> 2 weeks, immunosuppressive treatment, primary cellular immune deficiency) * decision to limit or stop therapy

Design outcomes

Primary

MeasureTime frame
Perioperative plasma concentration in 3HM24 hours postoperatively

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026